Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease

Donato Rigante, Claudia Fabiani, Jurgen Sota, Antonio Vitale, Giacomo Emmi, Lorenzo Vannozzi, Rossella Franceschini, Daniela Bacherini, Bruno Frediani, Mauro Galeazzi, Gian Marco Tosi, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)

Abstract

PURPOSE: To evaluate golimumab (GOL) efficacy in the management of Behçet's disease (BD)-related uveitis. METHODS: We retrospectively collected data from 5 patients (8 eyes) with at least two recent relapses of uveitis, treated with GOL at the standard dose of 50 mg every 4 weeks. RESULTS: A complete control of intraocular inflammation was observed in 7/8 eyes (87.5%) at 12-month follow-up. The number of relapses 12 months before and after GOL initiation was 11 and 1, respectively. At baseline, four eyes had active retinal vasculitis (RV). At 3-month follow-up evaluation RV resolved in all eyes. Mean Best Corrected Visual Acuity was 6.93 ± 4.34 at baseline and 7.32 ± 3.87 at 12-months follow-up. CONCLUSION: We confirm GOL efficacy in reducing intraocular inflammation in BD, both in term of reduction in the number of uveitis relapses and in achieving a prompt resolution of active RV.
Lingua originaleEnglish
pagine (da-a)1-6
Numero di pagine6
RivistaOcular Immunology and Inflammation
Volume2017
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Behçet's disease

Fingerprint

Entra nei temi di ricerca di 'Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease'. Insieme formano una fingerprint unica.

Cita questo